Literature DB >> 33728464

Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.

Sarah Haebe1, Tanaya Shree1, Anuja Sathe1, Grady Day1, Debra K Czerwinski1, Susan M Grimes2, HoJoon Lee1, Michael S Binkley3, Steven R Long4, Brock Martin4, Hanlee P Ji1,2, Ronald Levy1.   

Abstract

Tumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical implications is still limited. Here, we profiled 2 nodal, synchronously acquired tumor samples from 10 patients with follicular lymphoma (FL) using single-cell RNA, B-cell receptor (BCR) and T-cell receptor sequencing, and flow cytometry. By following the rapidly mutating tumor immunoglobulin genes, we discovered that BCR subclones were shared between the 2 tumor sites in some patients, but in many patients, the disease had evolved separately with limited tumor cell migration between the sites. Patients exhibiting divergent BCR evolution also exhibited divergent tumor gene-expression and cell-surface protein profiles. While the overall composition of the tumor microenvironment did not differ significantly between sites, we did detect a specific correlation between site-to-site tumor heterogeneity and T follicular helper (Tfh) cell abundance. We further observed enrichment of particular ligand-receptor pairs between tumor and Tfh cells, including CD40 and CD40LG, and a significant correlation between tumor CD40 expression and Tfh proliferation. Our study may explain discordant responses to systemic therapies, underscores the difficulty of capturing a patient's disease with a single biopsy, and furthers our understanding of tumor-immune networks in FL.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33728464      PMCID: PMC8160505          DOI: 10.1182/blood.2020009855

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  49 in total

1.  Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Authors:  Franck Morschhauser; Ian W Flinn; Ranjana Advani; Laurie H Sehn; Catherine Diefenbach; Kathryn Kolibaba; Oliver W Press; Gilles Salles; Hervé Tilly; Andy I Chen; Sarit Assouline; Bruce D Cheson; Martin Dreyling; Anton Hagenbeek; Pier Luigi Zinzani; Surai Jones; Ji Cheng; Dan Lu; Elicia Penuel; Jamie Hirata; Michael Wenger; Yu-Waye Chu; Jeff Sharman
Journal:  Lancet Haematol       Date:  2019-03-29       Impact factor: 18.959

2.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

3.  Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Authors:  Ranjana Advani; Andres Forero-Torres; Richard R Furman; Joseph D Rosenblatt; Anas Younes; Hong Ren; Kate Harrop; Nancy Whiting; Jonathan G Drachman
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

4.  Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse.

Authors:  Martin Wartenberg; Peter Vasil; Christian Meyer zum Bueschenfelde; German Ott; Andreas Rosenwald; Falko Fend; Marcus Kremer
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

5.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Authors:  Matthew J Frank; Patrick M Reagan; Nancy L Bartlett; Leo I Gordon; Jonathan W Friedberg; Debra K Czerwinski; Steven R Long; Richard T Hoppe; Robert Janssen; Albert F Candia; Robert L Coffman; Ronald Levy
Journal:  Cancer Discov       Date:  2018-08-28       Impact factor: 39.397

Review 6.  Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry.

Authors:  Anna Lucia Peluso; Antonio Ieni; Chiara Mignogna; Pio Zeppa
Journal:  Acta Cytol       Date:  2016-08-25       Impact factor: 2.319

7.  Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints.

Authors:  Noemi Andor; Erin F Simonds; Debra K Czerwinski; Jiamin Chen; Susan M Grimes; Christina Wood-Bouwens; Grace X Y Zheng; Matthew A Kubit; Stephanie Greer; William A Weiss; Ronald Levy; Hanlee P Ji
Journal:  Blood       Date:  2018-12-27       Impact factor: 22.113

8.  The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells.

Authors:  Cole Trapnell; Davide Cacchiarelli; Jonna Grimsby; Prapti Pokharel; Shuqiang Li; Michael Morse; Niall J Lennon; Kenneth J Livak; Tarjei S Mikkelsen; John L Rinn
Journal:  Nat Biotechnol       Date:  2014-03-23       Impact factor: 54.908

9.  Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Authors:  Shamzah Araf; Jun Wang; Koorosh Korfi; Celine Pangault; Eleni Kotsiou; Ana Rio-Machin; Tahrima Rahim; James Heward; Andrew Clear; Sameena Iqbal; Jeff K Davies; Peter Johnson; Maria Calaminici; Silvia Montoto; Rebecca Auer; Claude Chelala; John G Gribben; Trevor A Graham; Thierry Fest; Jude Fitzgibbon; Jessica Okosun
Journal:  Leukemia       Date:  2018-02-08       Impact factor: 11.528

10.  High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice.

Authors:  Adeline Crinier; Pierre Milpied; Bertrand Escalière; Christelle Piperoglou; Justine Galluso; Anaïs Balsamo; Lionel Spinelli; Inaki Cervera-Marzal; Mikaël Ebbo; Mathilde Girard-Madoux; Sébastien Jaeger; Emilie Bollon; Sami Hamed; Jean Hardwigsen; Sophie Ugolini; Frédéric Vély; Emilie Narni-Mancinelli; Eric Vivier
Journal:  Immunity       Date:  2018-11-06       Impact factor: 31.745

View more
  9 in total

1.  Tee-ing up a New Follicular Lymphoma Classification System.

Authors:  Ari M Melnick
Journal:  Blood Cancer Discov       Date:  2022-09-06

2.  Germinal centre-driven maturation of B cell response to mRNA vaccination.

Authors:  Wooseob Kim; Julian Q Zhou; Stephen C Horvath; Aaron J Schmitz; Alexandria J Sturtz; Tingting Lei; Zhuoming Liu; Elizaveta Kalaidina; Mahima Thapa; Wafaa B Alsoussi; Alem Haile; Michael K Klebert; Teresa Suessen; Luis Parra-Rodriguez; Philip A Mudd; Sean P J Whelan; William D Middleton; Sharlene A Teefey; Iskra Pusic; Jane A O'Halloran; Rachel M Presti; Jackson S Turner; Ali H Ellebedy
Journal:  Nature       Date:  2022-02-15       Impact factor: 69.504

3.  Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.

Authors:  Kelly L Mooney; Debra K Czerwinski; Tanaya Shree; Matthew J Frank; Sarah Haebe; Brock A Martin; Stefano Testa; Ronald Levy; Steven R Long
Journal:  Cancer Cytopathol       Date:  2021-11-15       Impact factor: 4.264

Review 4.  The follicular lymphoma epigenome regulates its microenvironment.

Authors:  Rada Amin; Mounia S Braza
Journal:  J Exp Clin Cancer Res       Date:  2022-01-12

5.  Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccination.

Authors:  Wooseob Kim; Julian Q Zhou; Alexandria J Sturtz; Stephen C Horvath; Aaron J Schmitz; Tingting Lei; Elizaveta Kalaidina; Mahima Thapa; Wafaa B Alsoussi; Alem Haile; Michael K Klebert; Teresa Suessen; Luis Parra-Rodriguez; Philip A Mudd; William D Middleton; Sharlene A Teefey; Iskra Pusic; Jane A O'Halloran; Rachel M Presti; Jackson S Turner; Ali H Ellebedy
Journal:  bioRxiv       Date:  2021-11-02

6.  Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin.

Authors:  Waleed Alduaij; Laura K Hilton; Muntadhar Al Moosawi; Susana Ben-Neriah; Barbara Meissner; Merrill Boyle; Kelly Mekwunye; David W Scott; Heather A Leitch; Jeffrey W Craig
Journal:  Hemasphere       Date:  2022-03-29

7.  PARP14 is a novel target in STAT6 mutant follicular lymphoma.

Authors:  Michael Mentz; William Keay; Verena Passerini; Oliver Weigert; Carolin Dorothea Strobl; Martina Antoniolli; Louisa Adolph; Michael Heide; Axel Lechner; Sarah Haebe; Elisa Osterode; Robert Kridel; Christoph Ziegenhain; Lucas Esteban Wange; Johannes Adrian Hildebrand; Tanaya Shree; Elisabeth Silkenstedt; Annette M Staiger; German Ott; Heike Horn; Monika Szczepanowski; Julia Richter; Ronald Levy; Andreas Rosenwald; Wolfgang Enard; Ursula Zimber-Strobl; Michael von Bergwelt-Baildon; Wolfgang Hiddemann; Wolfram Klapper; Marc Schmidt-Supprian; Martina Rudelius; Deepak Bararia
Journal:  Leukemia       Date:  2022-07-18       Impact factor: 12.883

8.  Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.

Authors:  Haoxun Zhang; Yiwen Liu; Bowen Wang; Chunyang Wang
Journal:  BMC Genom Data       Date:  2022-07-26

9.  SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.

Authors:  Wafaa B Alsoussi; Sameer K Malladi; Julian Q Zhou; Zhuoming Liu; Baoling Ying; Wooseob Kim; Aaron J Schmitz; Tingting Lei; Stephen C Horvath; Alexandria J Sturtz; Katherine M McIntire; Birk Evavold; Fangjie Han; Suzanne M Scheaffer; Isabella F Fox; Luis Parra-Rodriguez; Raffael Nachbagauer; Biliana Nestorova; Spyros Chalkias; Christopher W Farnsworth; Michael K Klebert; Iskra Pusic; Benjamin S Strnad; William D Middleton; Sharlene A Teefey; Sean P J Whelan; Michael S Diamond; Robert Paris; Jane A O'Halloran; Rachel M Presti; Jackson S Turner; Ali H Ellebedy
Journal:  bioRxiv       Date:  2022-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.